Yes, the 100% cash option is definitely one of three...

First 16 Last

Share
Profile

Follow
Hemis

47 Posts.

7

18/08/22

21:09

Post #: 63199879
Share

Originally posted by fourdollars: ↑

The MLD Board will roll out the "certainty of value" argument for rejecting the (hopefully initial) NRW bid. Its not clear at this stage whether all shareholders would have been able to select the 100% cash option and since the other options have exposure to the NRW shareprice, the MLD directors will say that the true value of the NRW proposal is unknown.

So hopefully one of three things happens now:

1. NRW makes it clear that all shareholders are able to accept the $1.085 / share offer in cash. If this happens, MLD Directors have no option but to recommend that NRW offer as it's superior.

2. NRW clarifies that not all shareholders can elect to receive 100% cash, but lifts its offer sufficiently so that there's a high likelihood that all shareholders will realise value in excess of the Theiss offer.

3. Theiss revises its offer to north of $1.085 and confirms that in all other respects, the terms of the offer as as per the current one. This may shut down what is now going to be a messy process with shareholders reluctant to accept the initial offer.

No one should be selling at the moment. Worst case you'll get $1.025/share (of which 2.5c may be a franked dividend, so its closer to $1.035). Best case Theiss and NRW will commence a bidding war and we'll get a price that's likely to be at least $1.085/share.

Expand

Yes, the 100% cash option is definitely one of three options:

https://hotcopper.com.au/threads/ann-nrw-confirms-maca-mld-approach.6901765/?post_id=63194089

Something definitely stinks. First the board recommends a low-ball offer from Thiess, then they don't bring the NRW bid to the attention of shareholders, now they reject a higher offer than Thiess'. They are clearly not acting in the interests of shareholders.

MLD Price at posting: $1.01 Sentiment: Hold Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

OJC

SPC to merge with Original Juice Co and Nature One Dairy

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one